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Abstract
Recently, there has been a resurgence of malaria in densely populated areas of the United States secondary to human
migration from endemic areas where factors such as cessation of vector control, vector resistance to insecticides, disease
resistance to drugs, environmental changes, political instability, and indifference, have played a role for malaria becoming an
overwhelming infection of these tropical underdeveloped countries. It is important for health care providers of gravida to be
alert of the disease and its effects on pregnancy.
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Introduction
In the US, malaria was endemic until the beginning
of the twentieth century with more than 500,000
cases per year. Malaria has a worldwide distribution
with an incidence of 300–500 million cases per year
with over 1–3 million deaths from the disease
annually [1,2]. Despite a worldwide effort to curb
the disease through vector control and treatment of
the disease, resurgence has developed due to
Plasmodium falciparum resistance.
Because of today’s ease of travel and continental
migration throughout the world, malaria has caused
occasional outbreaks in densely populated areas of
the United States [3–5]. There are 60 new cases
reported in Florida annually [6].
It is important to recognize that pregnant patients
at risk for malaria require immediate treatment. The
effect of malaria on the gravida and the fetus is
potentially severe and life-threatening, thus warrant-
ing a thorough understanding of its complications
and treatments.
Pathogenesis
Malaria is an infection usually transmitted by the bite
of an infected female Anopheles mosquito. The new
parasite life cycle begins when parasites of the family
Plasmodia enter the bloodstream after the mosquito
bite.
The four species of Plasmodium known to infect
humans are (in decreasing order of prevalence):
Plasmodium falciparum, P. vivax, P. malariae, and P.
ovale. Due to the similarity of symptoms, it is
virtually impossible to differentiate between the
species without examining a microscopic peripheral
blood smear. After a bite by an infected female
Anopheles mosquito, sporozoites are released from
the salivary gland of the mosquito and ﬁnd their way
to the human circulatory system starting the new
parasite life cycle (Figure 1). These sporozoites travel
to the liver invading hepatocytes to become the
mature tissue schizonts. At this stage of the P. vivax
and P. ovale life cycle, some of these schizonts
become dormant hypnozoites. Inside the hepatocyte,
an estimated 10,000 to 30,000 merozoites are
produced per each infected hepatocyte. Merozoites
are then released from the hepatocyte, each infecting
a red blood cell (RBC). Inside the RBC, the parasite
matures into a trophozoite, a schizont, and then into
an asexual form for replication which returns back
into the merozoite form. After 48–72 hours (depend-
ing on the species), approximately 25–30 merozoites
are released causing fever and symptoms. Inside the
RBC, some Plasmodia may convert to a sexual form
called a gametocyte. When a new female Anopheles
mosquito bites an infected human host, released
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mosquito. The gametocytes develop into either a
male or female gametocyte within the gut. Fertiliza-
tion occurs between male and female gametocytes,
producing a diploid zygote. This zygote develops into
an ookinete that invades the gut of the mosquito and
becomes an oocyst. The oocyst undergoes meiosis
producing haploid sporozoites that migrate to the
salivary gland of the mosquito. The cycle is
completed when this infected mosquito bites an
unfortunate host.
Plasmodia, in the sporozoite form, enters the
hepatocyte by binding to the circumsporozoite
protein (CSP) [7]. The presence of the Duffy antigen
has been demonstrated to be necessary for parasitic
invasion of RBC’s by P. vivax [8]. In P. falciparum,
several molecules on the surface of endothelial cells
act as receptors for infected RBCs [9–11].
P. falciparum infection causes cytoadherence of
affected red blood cells in the microvasculature of
the circulatory system which potentiates micro-
thrombi formation leading to microvascular disease.
The microthrombi affect a number of organs causing
various symptoms and pathologies.
In addition to the cytoadherence of RBCs to
endothelial cells in the microcirculation, the size,
shape, and pliability of the infected RBC changes.
The normal, 7–8 mm donut-shaped RBC, changes
into a smaller, less deformable 4–5 mm RBC. This
can also potentiate microthrombus formation.
The human host responds by producing cytokines,
interleukins, and tumor necrosis factor (TNF). The
fever caused by malaria is secondary to a release or
exposure to glycosyl phosphatidylinositol (GPI) from
the RBC surface during the time of RBC rupture and
merozoite release. As a result of this process, TNF-a
is then released from macrophages resulting in fever
[12,13].
Each species of Plasmodium has a preference for
RBC’s of speciﬁc age. This selectivity limits their
potential for reproduction and thereby the severity
and duration of infection. Plasmodium falciparum has
Figure 1. Life cycle of malaria parasite. An infected Anopheles mosquito bites and infects a human host starting its new malaria life cycle.
The cycle is completed when an uninfected mosquito bites an infected human host, becoming infected by the transmission of gametocytes
which then matures into sporozites inside the mosquito.
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form of the disease as it is capable of living in RBCs
of all ages. As a result, a higher level of parasitemia
can occur causing a more severe disease.
Sickle-cell trait has been shown to protect against
severe malarial disease. Sequestration in the micro-
vasculature where the oxygen tension is low inhibits
parasite growth in falciparum malaria, but not in
other Plasmodium infections. In addition to hemo-
globin S, hemoglobin C has been thought to be
protective [14]. More recently, HLA-Bw53 and
HLA-DRB1*1302 have been found to be protective
genes in speciﬁc populations protecting against
severe malaria [15,16].
Clinical ﬁndings of active disease
Malaria is a multi-organ disease. A relationship
between the level of parasitemia and risk of death
has been demonstrated [17]. Malaria tends to be
more severe in pregnant women, especially in non-
immune patients.
Malaria causes acute febrile illness with character-
istic febrile paroxysms every 48–72 hours. Depend-
ing on the general health of the patient and the
species of the parasite, the severity and course of the
attack will vary. Malaria often presents in 3 stages—
cold, hot and sweating stages. The cold stage begins
with a subjective feeling of cold that progresses to
severe shivering with a rapid thready pulse. The
duration of this stage lasts 15–60 minutes. Next, the
hot stage begins as the patient develops a fever that
can reach 104–1068F. The skin is ﬂushed and dry
with a rapid, full and bounding pulse lasting for 2–
6 hours. Finally, the sweating stage begins when the
temperature falls and the patient begins to sweat
profusely. In this stage the patient may become
dehydrated. The sweating stage lasts 2–4 hours.
After resolution of the three stages, the patient may
feel better for a short time before the cycle repeats
itself. The time interval between cycles depends on
the infecting parasite. P. vivax and P. ovale cycle
every 48 hours (tertian malaria), P. malariae cycles
every 72 hours (quartan malaria). P. falciparum
cycles have asynchronous intervals usually within
36–48 hours. If untreated, these cycles continue
from a week to longer than a month [18].
P. ovale and P. vivax are capable of remaining
dormant in the liver in the form of hypnozoites and
usually reappear in about 6–11 months causing a
relapse. P. malariae, on the other hand, may persist at
low levels in the circulation for up to 30 years
without liver involvement.
P. falciparum is considered an acute form of
malaria, usually with severe symptoms, and does
not relapse. Falciparum malaria can cause chronic
splenomegaly, hemolytic anemia, nausea and vomit-
ing, diarrhea, lactic acidosis, hypoglycemia, jaundice,
cerebral malaria, acute renal failure, severe anemia,
and rarely pulmonary edema.
Plasmodium vivax and P. ovale are usually de-
scribed together because they produce hypnozoites,
cycle every 48 hours, and have similar clinical
presentations. The hypnozoites can remain dormant
in the liver for 6–11 months before becoming active
and producing a relapse. Splenic rupture 2–3 months
after initial infection can occur. No microvascular
complications occur as with falciparum malaria. In
addition, parasitemia is usually less severe compared
with P. falciparum as only reticulocytes are affected
[19]. Furthermore, P falciparum suppresses hemato-
poiesis, whereas P. vivax and P. ovale have been
found to stimulate hematopoiesis.
Laboratory ﬁndings typically seen in malaria
include acute anemia, increased LDH, reticulocyto-
sis, and thrombocytopenia. In addition, proteinuria,
hemoglobinuria, elevated serum creatinine, hyperbi-
lirubinemia, elevated transaminases, lactic acidosis,
and hypoglycemia may be seen.
Screening and diagnosis
The diagnosis of malaria during pregnancy requires
laboratory conﬁrmation, usually by blood ﬁlm from a
ﬁngerstick. Light microscopy of Giemsa-stained
blood smears with oil-immersion is necessary for
speciﬁc parasite identiﬁcation. P. vivax and P. ovale
types of malaria have the characteristic Schuffner’s
dots allowing for easy identiﬁcation. The blood ﬁlm
offers a cheap, easy and effective means of diagnos-
ing malaria and the type of Plasmodium species
causing the infection. However, 5–7% of cases are
due to simultaneous infection with more than one
species.
Recently, new tests to diagnose malaria have
emerged. New dipstick tests (ICT-Malaria Pf,
OptiMALr and the Kat-Quick kits) can detect
histidine rich protein-2 (HRP-2) and/or parasite
speciﬁc lactate dehydrogenase (pLDH) in Plasmo-
dium falciparum infections. Studies have shown that
these new tests have sensitivities approaching 100%
[20] and show positive results up to 2 weeks after
successful treatment of malaria.
Another new method is the polymerase chain
reaction (PCR). With the use of PCR, it is possible
to detect 510 parasites/10 mL of blood. Zalis et al.
reported a PCR detection rate by ampliﬁcation
using ethidium bromide staining of the p126
P. falciparum gene of .005 parasites/mL without
radioactive material [21]. However, this method is
much more expensive than a blood ﬁlm and is not
readily available in many areas involved in the
epidemic.
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nevertheless malaria may persist for months after the
infection. For this reason, ELISA testing is more
useful for epidemiological purposes.
Malaria in pregnancy
Women living in endemic areas are considered to
have some immunity and malarial infections are
usually asymptomatic or with less severe symptoms
[22]. Conversely, the disease is almost always
symptomatic, and potentially lethal, in non-immune
patients particularly gravid females. This is thought
to be due to higher levels of circulating immuno-
suppressive corticosteroids in pregnant women
[23,24]. Preterm delivery, IUGR, abortion, still-
birth, eclampsia postpartum hemorrhage, puerperal
fever, and maternal/fetal death are some complica-
tions associated with malaria particularly with P.
falciparum. Women in their ﬁrst trimester of
pregnancy are at a high-risk of developing severe,
life-threatening malaria-associated complications.
Studies have shown that pregnant women attract
at least twice as many mosquitoes as non-pregnant
patients [25,26]. Risk factors for adverse outcomes
of women infected with malaria during pregnancy
include HIV + status, low parity, non-immune,
suboptimal treatment, and pregnancy during high-
transmission season [27].
When infection of the placenta occurs, an in-
creased risk of stillbirth and prematurity has been
noted [28]. The placenta becomes involved when
infected, adhesive RBCs sequester in the intervillous
space [2]. Deterioration in placental function may
occur, causing transient fetal hypoxia. Arbeille et al.
showed how the hypoxic index value during crisis
can predict an abnormal fetal heart at delivery [29].
Primigravidas appear to be at the highest risk [30]. Is
believed that in subsequent pregnancies, affected
women are protected from sequestration of RBCs in
part by antibodies that prevent cytoadhesion of
infected RBCs in the placenta [2].
Approximately 8–14% of LBW babies are a result
of preterm labor directly related to a malarial
infection, and about 3–14% of infant death is related
to the disease [3]. Precipitous labor and uterine
rupture have also been reported as complications of
malarial infection [31]. The incidence of malaria may
be higher in HIV-positive pregnant females accord-
ing to a study in Rwanda [32].
Anemia and thrombocytopenia are commonly
seen in all forms of malaria, but may be especially
severe with P. falciparum. Severe anemia results in
infected patients for two reasons. First is due to RBC
destruction associated with release of merozoites.
Secondly, the elevated TNF-a produced from
falciparum malarial infection causes suppression of
hematopoeisis. Thrombocytopenia also occurs more
commonly in pregnant patients with malaria and can
lead to prolonged and easy bleeding. Due to the
potentially harmful effects of malaria to both the
mother and the fetus in utero, it is therefore
recommended that these patients receive chemopro-
phylaxis to prevent malarial infection.
Hypoglycemia and lactic acidosis due to malaria is
seven times more frequent in pregnancy than in a
non-pregnant woman [33]. Lactic acidosis and
hypoglycemia result from hepatic involvement. Due
to the metabolic requirements of both the fetus and
the parasites, a pregnant woman may suffer from
severe hypoglycemia. The Plasmodium parasites not
only consume maternal glucose but also stimulate
the pancreatic beta cells, leading to hyperinsuline-
mia, and ultimately severe hypoglycemia [34,35].
The hypoglycemia is manifested by dizziness, blurred
vision, cold extremities, and hypotension. When
severe enough, the hypoglycemia can progress to
mental status changes and convulsions. Early recog-
nition and treatment of patients with falciparum
malaria and hypoglycemia can signiﬁcantly affect the
patient’s ultimate outcome [36].
Cerebral malaria is a common presentation in
pregnant patients. Particularly concerning is the
increased case-fatality rate of cerebral malaria in
pregnant patients of up to 50% [37]. Case-fatality
rates is approximately 20%, and 3% of patients
develop permanent neurologic sequelae [37]. Within
days to weeks a gravid patient may progress to
confusion, impaired consciousness, agitation, coma,
convulsions, shock, and death. The extent of
dysfunction is reﬂective upon virulence, immune
status of patient, delay in treatment, or a combina-
tion of the above. Patients surviving cerebral malaria
may have persistent sequela including speech dis-
orders, behavioral disorders, ataxia, hemiplegia,
epilepsy, and blindness.
Several complicated cases reported from China
described cerebral malaria with coma, high fever,
convulsions, anemia, and splenomegaly. Eclampsia,
blackwater fever, renal failure, cardiopulmonary
failure, postpartum hemorrhage, and puerperal infec-
tion were reported as causes of death in many of the
patients. Recommendation for early termination of
pregnancy in patients with eclampsia was described
as life-saving [38].
The oliguric acute renal failure associated with
falciparum malaria is relatively common in non-
immune patients. Microvascular disease causes an
occlusion in the renal vasculature thereby preventing
exchange of glucose and oxygen in the kidney.
Intravascular hemolysis allows free hemoglobin and
malarial pigment to damage the kidneys. This is
known as ‘‘blackwater fever’’. Dialysis for several
weeks may be necessary for survival in patients with
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and is caused by G6PD deﬁciency-related hemolysis
from antimalarial drugs and/or directly from the
malarial infection.
The main complication associated with P. malariae
is immune complex glomerulonephritis (parasite
antigen with host IgG) and usually occurs 3–6
months after transmission [39]. No microvascular
complications are seen with this form of malaria. P.
malariae usually produces mild symptoms and
produces acute illness only in immunocompromised
patients. However, parasitemia may persist for up to
20–30 years.
Although uncommon, pulmonary edema can also
result from microvascular compromise causing
ARDS [35,39]. It is believed that TNF-a by itself
can produce the severe pulmonary edema and ARDS
observed in falciparum malaria [40]. Treatment with
artiﬁcial ventilation may be life-saving.
Antimalarial medications
Aminoquinolones act by inhibiting heme polymerase
the enzyme responsible for breakdown of the toxic
hemoglobin in the food vacuole of the parasite [41].
As a result, the hemoglobin accumulates and lyses
the cell membrane. Drugs in this class approved in
the US include chloroquine, quinidine, hydroxy-
chloroquine and the newer aminoquinolones,
meﬂoquine and halofantrine. The drug regimen
chosen for prophylaxis and treatment of malaria
depends on the suspected species of Plasmodium
parasite and the patient’s ability to take medication.
Chloroquine, a Category C drug, has been the
treatment of choice for almost 50 years especially in
pregnancy. However, resistance of P. falciparum and
P. vivax is becoming widespread in endemic areas.
Chloroquine is used as a single ﬁrst-line treatment in
many areas for P. vivax, P. malariae, and P. ovale, or
in combination with another drug. It may be given
intravenously if the patient is unable to tolerate oral
medications. Chloroquine must be given very carefully
because cardiac arrhythmias may develop. Pregnan-
cies exposed to chloroquine have not demonstrated
increased rates of congenital abnormalities, stillbirth,
or low birth weight and the drug is considered safe in
the ﬁrst trimester [42] and breastfeeding. Primi-
parous mothers have been shown to beneﬁt from
chloroquine prophylaxis in pregnancy by reducing
the risk of anemia at birth [43]. In addition,
chloroquine has been shown to inhibit release of
TNF-a [12,44].
Hydroxychloroquine is another aminoquinolone
that is used mainly for prophylaxis. It is effective
against all Plasmodia except chloroquine-resistant P.
falciparum.
Quinine is effective in vivo against all strains of
malaria, especially in chloroquine-resistant infec-
tions, but has a high gametocyte carriage rate. The
combination of quinine with clindamycin has been
used as a back-up for quinine/artesunate resistant P.
falciparum [45]. High ﬁrst dose quinine provides
increased parasite clearance but is a known abortafa-
cient at high doses and can cause transient partial
hearing loss as well.However, pregnancies exposed to
quinine have not shown an increased rate of
congenital abnormalities, stillbirth, or low birth-
weight and the drug is considered safe in the ﬁrst
trimester [42]. Furthermore, quinine has been shown
to prevent premature contractions and fever in
pregnant women [46]. Quinine is not available in
the US, but the antiarrthymic quinidine is substituted
for quinine [47]. Quinidine is listed as a Category C
drug and considered safe in breast-feeding patients.
Due to the high resistance rates of Plasmodium,
both prophylaxis and treatment regimens are tailored
to the speciﬁc region from which the patient was
infected. Meﬂoquine is effective against all Plasmodia
and has been shown to shorten the parasite clearance
time compared with quinine in susceptible species
[48]. It is relied upon in nearly every endemic area
[37]. Meﬂoquine has been shown to be safe in the
second and third trimesters, but there is not
sufﬁcient evidence to promote its use during the
ﬁrst trimester [22]. It is listed as Category C, has not
been associated with abortion, low birth weight,
mental retardation, or congenital abnormalities.
However, an increased risk of stillbirth has been
demonstrated [49]. If the parasite is resistant to
meﬂoquine, halofantrine should not be used.
Another new drug that has been shown to be
reliable in resistant species is halofantrine. It is not
used prophylactically. It is effective against all
sensitive Plasmodia in the asexual merozoite form.
This drug should not be used in meﬂoquine-resistant
infections as the mechanism of action is the same.
Halofantrine can produce prolongation of the QT
interval of an electrocardiogram, and may cause
ventricular arrhythmias. This drug is listed as a
category C but considered contraindicated in preg-
nant or lactating women.
Primaquine is used for treatment of hypnozoites in
P. vivax and P. ovale infections. It is listed as Categ-
ory C with an uncertain breast-feeding safety proﬁle.
Proguanil is a new drug that is effective against
early tissue schizonts of P. vivax infections. It may be
used for prophylaxis of pregnant women and non-
immune patients at risk. It can be used with
chloroquine for prophylaxis in areas of low preva-
lence of chloroquine resistance. The newly approved
Malarone
TM, a combination of proguanil and
atovaquone, may be used to treat acute uncompli-
cated falciparum malaria.
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used outside the US for uncomplicated cases of
malaria. It is similar to chloroquine and usually used
in conjunction with artesunate. When used by
travelers for prophlaxis, fatal adverse drug reactions
have been reported [50,51].
Several derivatives of the Chinese herb, Qinghao-
su, are used in the treatment of malaria outside the
US. Artemesinin, artesunate, artemether, and ar-
teether are some examples. These drugs are effective
against all species of Plasmodia especially in chlor-
oquine-resistant P. falciparum. Artesunate has been
shown to shorten the parasite clearance time in
susceptible patients compared with quinine [48].
Artesunate suppositories have been shown to be as
effective as intravenous administration in treating
P. falciparum [52,53]. The drug appears to be well
tolerated with no evidence of adverse effects sig-
niﬁcantly different from controls [54].
Although pyrimethamine is primarily used to treat
toxoplasmosis in the US, it may also be used to treat
malaria. Pyrimethamine combined with chloroquine
can be used to eradicate the latent hepatic phase
of P. vivax and P. ovale infections. However, folic
acid should be given to prevent deﬁciency. When
possible, treatment with pyrimethamine should be
delayed until after delivery of the fetus, because of
the increased risk of hemolytic anemia in the fetus
[13]. Even though resistance to pyrimethamine is
common, dapsone combined with pyrimethamine is
useful in resistant cases. It is listed as a Category C
drug and considered safe during pregnancy.
Sulfadoxine is a sulfa drug not available in the
US that is combined with pyrimethamine for the
treatment of chloroquine-resistant P. falciparum.
Fansidar
1, the combination of pyrimethamine and
sulfadoxine, can cause potentially fatal Stevens-
Johnson syndrome and is no longer used. Signiﬁcant
levels in the newborn can occur that may persist for
days after delivery when given near term. This drug
can cause jaundice, hemolytic anemia and potentially
kernicterus in the newborn.Sulfa drugs are considered
safe in breast-feeding and are listed as Category B.
Although not used for prophylaxis, teytracycline
may be used in combination with other drugs for the
treatment of malaria. Combined with quinine, tetra-
cycline can be used against resistant P. falciparum.I t
is not used for prophylaxis. A longer-acting derivative
of tetracycline, doxycycline, is also used in treatment
of malaria. It is used in patients unable to tolerate
meﬂoquine or reside in meﬂoquine-resistant areas.
However, both are Category D drugs and are not
recommended in pregnancy or breastfeeding mothers.
As a general rule, non-immune patients should be
hospitalized for treatment to prevent and/or treat
complications of falciparum malaria, especially when
pregnant. Semi-immune patients can usually be
treated as an outpatient for all species of malaria.
For patients with high levels of parasitemia exceeding
15% and in addition to medications, exchange
transfusion may be considered [55]. However, pa-
tients with parasitemias exceeding 50% have survived
without exchange transfusion [56]. Treatment with
corticosteroids was used for many years in the
treatment of cerebral malaria but has been shown
to be harmful as evidenced by longer duration of
coma and worse outcomes [57]. Therefore, steroids
should no longer be used in cerebral malaria.
Congenital malaria
Congenital malaria affects 7% of newborns in
endemic areas. Malarial induced anemia in a
pregnant patient is serious, because it can affect the
oxygen delivery to the developing fetus. This anemia
has been linked to infants born with low birth weight
and even spontaneous abortions due to fetal hypoxia
[34]. Steketee et al. estimated a yearly worldwide
infant mortality of 75,000–200,000 directly related to
malaria in pregnancy [58].
The level of parasitemia is proportional to the
degree of anemia, thus a higher level of parasites in
the blood results in a more profound anemia, hence a
greater chance for fetal growth complications. It was
also hypothesized that malarial infection of the
placenta leads to a generalized placental thickening,
thus hindering the passage of oxygen and nutrients
and leading to fetal growth retardation [22].
In a study conducted by McGregor of Gambian
pregnancies, it was discovered that the average birth
weight of primagravidas infected with malaria was
150 g below normal, while there were no statistically
signiﬁcant difference seen in the birth weights of
infants from multi-gravid females [59,22].
Prevention
In areas with a high prevalence of malarial para-
sitemia and anemia, prophylaxis with a drug proven
to be effective for that particular area should be
considered during pregnancy [60]. In fact, when
drugs were given routinely for prophylaxis locally
active for malaria the incidence of low birth weight
and anemia was reduced. However, the effect
appears to be limited to women with low parity
[43,61]. Despite reports of resistance of P. falciparum
to chloroquine, the beneﬁt in reducing anemia at
delivery was still noted.
Chemoprophylaxis should be started 2 weeks in
advance to travel and should be continued for 4
weeks after return. Chloroquine is the agent of
choice for prophylaxis and is considered safe for
pregnant women and children. For chloroquine-
resistant areas, meﬂoquine should be used. In
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preventing disease especially in primigravidas. Re-
ports have indicated that meﬂoquine is safe [62].
Early studies involving the SPf66 vaccine demon-
strated 10–30% effectiveness [63]. More recently,
the SPf66 malaria vaccine has appeared to signiﬁ-
cantly reduce initial attacks of P. falciparum malaria
according to a Cochrane collaborative review [64].
Conclusions
With the resurgence of malaria, the widespread harm
caused by the disease and with the potential to
spread beyond its current endemic areas, medical
professionals must be vigilant to the prevention,
recognition and treatment of malaria while being
aware that malaria can have additional effects on the
mother and fetus. Knowledge of this additional
information will provide the health care provider
with the best tools to provide the best opportunity for
positive outcomes for mother, fetus and the com-
munity. For the most up-to-date information on
malaria visit the ‘‘Roll Back Malaria’’ website
[www.rbm.who.int]. There are many treatment regi-
mens available, and the most up to date treatment
protocols in the US can be obtained from the CDC’s
malaria hotline at (404) 332–4555 and on the CDC
travel website [http://www.cdc.gov/travel].
Even though there are inherent risks associated
with treatment of malaria, these risks are outweighed
by the potential harm that may caused to the fetus
in utero and the mother and can even result in death.
Thus treatment of pregnant females with malaria is
certainly indicated.
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